Neonatal Pharmacy Resident Small Research Grant

NOTE: Program is temporarily suspended and not accepting new applications at this time.

Purpose
 
The Neonatal Pharmacy Resident/Fellow Research Grant supports research in neonatal medication use conducted by pharmacy residents (e.g., PGY-1, PGY-2 pediatric pharmacy resident) and fellows. The primary purpose of the research award is to improve safe and effective use of medications in neonates. Research projects can comprise a wide range of medication-use topics, including but not limited to: technology, safety, and/or pharmacotherapy. A secondary goal of the program is to develop and strengthen the skills of pharmacy residents and fellows by fostering development of mentoring relationships with more experienced senior investigators.
 
Eligibility Criteria
 
The proposed research must involve health services research in neonatal medication use that is conducted by a pharmacy resident (e.g., PGY-1, PGY-2 pediatric pharmacy resident) or fellow. The principal investigator must be a pharmacy resident or fellow and a licensed pharmacist in the country in which they practice. A mentor/advisor must participate in the research project and will be designated as a co-investigator. Both the principal investigator and the mentor/advisor must be members of PPAG. In the application process and grant progress reports, evidence must be included regarding the support and involvement of the mentor/advisor. The proposed study must be approved by an institutional review board (IRB) at the institution at which the research will occur. Evidence of IRB submission must be provided to PPAG with the submitted proposal. Grant funds will not be disbursed until evidence of IRB approval has been received. Multidisciplinary research teams are strongly encouraged. The grant recipients agree to present their results at a PPAG conference (encore presentation is acceptable) and publish the results of their research in a peer-reviewed scientific journal. Publication in the Journal of Pediatric Pharmacology and Therapeutics is encouraged.
 
Funding Information
 
Up to three grants (up to $2,000 each) may be awarded yearly. Grants are awarded to pharmacy residents and/or fellows to provide funding for specific neonatal research related to medication use and are not intended for long-term support of research programs.
 
Funds may be applied to:

  1. Salary support for consultants such as a biostatistician
  2. Institutional Review Board fees
  3. Supplies necessary to complete the proposed study
  4. Travel necessary to conduct the proposed study
  5. Patient expenses/reimbursement for participation
  6. Travel to disseminate research results

 

Funds may not be applied to:

  1. Resident/fellow salaries and/or benefits
  2. Ongoing general operating expenses
  3. Purchase of permanent equipment or facilities (or other capital costs)
  4. Endowment contributions
  5. Stipends/loans

 

Application Process

  1. Pharmacy residents (e.g., PGY-1, PGY-2 pediatric pharmacy resident) or fellows must download and fill out the application. DOWNLOAD MS WORD APPLICATION
  2. Completed applications can be emailed to: matthew.helms@ppag.org on or before the application deadline.

 

Proposal Review
Grants will be awarded based on merits of the proposal as listed below:

  1. RATIONALE (10 points maximum)
  2. SIGNIFICANCE (25 points maximum)
  3. METHODS (25 points maximum)
  4. CAREER DEVELOPMENT (10 points maximum)
  5. INVESTIGATORS (10 points maximum)
  6. PATIENTS AND FACILITIES; FEASIBILITY (10 points maximum)
  7. BUDGET (5 points maximum)
  8. APPLICATION PROCEDURES (5 points maximum)

 

A review committee will consist of members from the PPAG Research Committee and the Neonatal Special Interest Group. The review committee will receive and review proposals and determine awardees.
 
Deadline
Proposals must be received by PPAG by October 15th. Grant awardees will be informed by November 1st of each year.
 
Past Recipients

2009

Project Title: Impact of Gavsicon on blood aluminum levels in preterm neonates receiving treatment for gastroesophageal reflux
Investigator: Keliana O'Mara, PharmD; Neonatal Pharmacology Fellow, Women's Hospital of Greensboro, NC

Project Title: Parenteral Nutrition Associated Liver Disease: Early Markers and Therapy with enteral omega-3 Supplementation
Investigator: Emma Tillman, PharmD; Fellow, The University of Tennessee Health Science Center, Memphis, TN

2010

Project Title: Gentamicin pharmacokinetics in neonates undergoing therapeutic hypothermia
Investigator: Liana Mark, PharmD; PGY1 Pharmacy Practice Resident, The Johns Hopkins Hospital, Baltimore, MD

Project Title: Concentration dependent effects of eicosapentaenoic acid and docosahexaenoic acid on bile acid induced apoptosis in HepG2 cell
Investigator: Emma Tillman, PharmD; Fellow, The University of Tennessee Health Science Center, Memphis, TN

2011

Project Title: Optimum concentration of eicosapentaenoic acid and docosahexaenoic acid on bile acid induced apoptosis in HepG2 cell
Investigator: Oscar Rafael Herrera, PharmD; Fellow, The University of Tennessee Health Science Center, Memphis, TN

2012

Project Title: Neonatal indomethacin for prevention of intraventricular hemorrhage: a study of plasma concentrations, pharmacogenomic factors, and outcomes
Investigator: Deborah Raithel, PharmD; PGY2 Pediatric Pharmacy Resident, University of Illinois- Chicago, Chicago, IL

2013

Project Title: Protein and energy intake during the first week of life and brain growth and development in preterm neonates
Investigator: Caren Liviskie, PharmD; PGY2 Pediatric Pharmacy Resident, St. Louis Children's Hospital, St. Louis. MO

2014

Project Title: Comparison of amikacin pharmacokinetics in neonates pre and post a dosing protocol change
Investigator: Kaitlin Hughes, PharmD; PGY2 Pediatric Pharmacy Resident, The University of Oklahoma, Oklahoma City, OK

Project Title: Evaluation of the effects of extracorporeal life support on antiepileptic drug serum
Investigator: Nicholas Dillman, PharmD; PGY2 Pediatric Pharmacy Resident, Texas Children's Hospital, Houston, TX

2015

Project Title: Efficacy of a pharmacist-managed epoetin alfa protocol for anemia of prematurity
Investigator: Laurie Wright, PharmD; PGY2 Pediatric Pharmacy Resident, Community Regional Medical Center, Fresno, CA